Resminostat
CAS: 864814-88-0
Ref. 3D-FR138825
| 1mg | A consultar | ||
| 2mg | A consultar | ||
| 5mg | A consultar | ||
| 10mg | A consultar | ||
| 25mg | A consultar |
Informação sobre produto
- (2E)-3-[1-({4-[(Dimethylamino)methyl]phenyl}sulfonyl)-1H-pyrrol-3-yl]-N-hydroxyacrylamide
- (E)-3-[1-[[4-[(Dimethylamino)methyl]benzene]sulfonyl]-1H-pyrrol-3-yl]-N-hydroxyacrylamide
- 4SC 201
- (2E)-3-[1-[[4-[(Dimethylamino)methyl]phenyl]sulfonyl]-1H-pyrrol-3-yl]-N-hydroxy-2-propenamide
- 2-Propenamide, 3-[1-[[4-[(dimethylamino)methyl]phenyl]sulfonyl]-1H-pyrrol-3-yl]-N-hydroxy-, (2E)-
Resminostat is a small molecule that inhibits the transcriptional co-activator, pd-l1. It has been shown to be very effective at reducing the growth of squamous cell carcinoma cells in vitro and in vivo. Resminostat also reduces liver fat content and steatosis by inhibiting fatty acid synthesis. Resminostat has been shown to induce apoptosis in cancer cells through inhibition of nuclear DNA replication, which leads to decreased production of proteins required for cell division. This drug has not been tested on humans but is being investigated as a potential treatment for hepatic steatosis, a condition characterized by excess fat accumulation in the liver.
Propriedades químicas
Consulta técnica sobre: 3D-FR138825 Resminostat
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.
